Maharshi Badri Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 24-10-2024
- Paid Up Capital ₹ 2.00 M
as on 24-10-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.44 M
as on 24-10-2024
- Revenue 13.52%
(FY 2023)
- Profit 14.82%
(FY 2023)
- Ebitda -5.83%
(FY 2023)
- Net Worth 7.39%
(FY 2023)
- Total Assets 19.74%
(FY 2023)
About Maharshi Badri Pharmaceuticals
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 2.00 M.
The company has closed loans amounting to ₹4.44 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Madan Lal, Sanjay Kumawat, and Uday Singh serve as directors at the Company.
- CIN/LLPIN
U24232RJ2007PTC024162
- Company No.
024162
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Maharshi Badri Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madan Lal  | Director | 01-Jan-2008 | Current |
| Sanjay Kumawat | Director | 02-Feb-2024 | Current |
| Uday Singh | Director | 09-Apr-2007 | Current |
Financial Performance of Maharshi Badri Pharmaceuticals.
Maharshi Badri Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.52% increase. The company also saw a substantial improvement in profitability, with a 14.82% increase in profit. The company's net worth moved up by a moderate rise of 7.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maharshi Badri Pharmaceuticals?
In 2023, Maharshi Badri Pharmaceuticals had a promoter holding of 52.50% and a public holding of 47.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ramam Organics Private LimitedActive 6 years 8 monthsMadan Lal and Sanjay Kumawat are mutual person
- Scrapking Dotcom Private LimitedActive 6 years 8 months
Madan Lal and Sanjay Kumawat are mutual person
- Brit10 Pharmaceuticals Private LimitedActive 6 years 8 months
Madan Lal and Sanjay Kumawat are mutual person
- Janak Bhoomi Builders Private LimitedActive 4 years 1 month
Madan Lal and Sanjay Kumawat are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 31 Oct 2012 | ₹4.00 M | Satisfied |
Punjab National Bank Creation Date: 02 Jul 2010 | ₹0.44 M | Satisfied |
How Many Employees Work at Maharshi Badri Pharmaceuticals?
Unlock and access historical data on people associated with Maharshi Badri Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maharshi Badri Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maharshi Badri Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
